Regentis Biomaterials Secures Patent For Liquid, Ready-To-Use GerlinC Formulation, Enhancing Efficiency In Knee Cartilage Repair

Patent protects ready to use liquid formulation of GerlinC which improves efficiency and focus for surgeons, resulting in a 10-minute procedure

Robust IP portfolio includes 35 issued patents to date worldwide

GerlinC is in a pivotal FDA trial, has received regulatory approval in the EU, and is the world's first off-the-shelf regenerative treatment for knee cartilage repair

HERZLIYA, IL / ACCESS Newswire / December 18, 2025 / Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced that the U.S. Patent and Trademark Office has issued the Company a patent titled "Organic Solvent Free Compositions Compromising Protein-Polymer Conjugates and Uses Thereof" for its lead product, GerlinC®, addressing the liquid, ready to use version of the product, as well as improved processes for its production that avoid the use of organic solvents.

This patent's primary claims are focused around GelrinC's liquid ready-to-use formulation, reflecting Regentis' focus on simplifying procedures for surgeons while improving patient experience. GelrinC is delivered in liquid form to conform precisely to the geometry of the cartilage wound and is then cured using UV light to form an elastomeric, temporary, programmed implant. The straightforward, approximately 10-minute procedure eliminates complex preparation steps and distractions for surgeons and enables a brief, convenient office visit for patients.